![](https://www.diabetesnews.com/wp-content/uploads/2014/02/2D192335-AFCD-4BA8-A40556BD25679949-150x150.jpg)
A recent agreement between Zosano Pharma, Inc. and Novo Nordisk could lead to the introduction of a once-weekly drug for type 2s that is administered via a micro-needle patch system.
Read more
A recent agreement between Zosano Pharma, Inc. and Novo Nordisk could lead to the introduction of a once-weekly drug for type 2s that is administered via a micro-needle patch system.
Read more